Ribavirin (R) — Competitive Intelligence Brief

Ribavirin (R) (Ribavirin (R)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Virology/Infectious Disease.

marketed Nucleoside analog antiviral Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism Virology/Infectious Disease Small molecule

Target snapshot

Ribavirin (R) (Ribavirin (R)) — Tibotec Pharmaceuticals, Ireland. Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ribavirin (R) TARGET	Ribavirin (R)	Tibotec Pharmaceuticals, Ireland	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism
ribavirin pre-treatment	ribavirin pre-treatment	University of Roma La Sapienza	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Masked Oral Valacyclovir	Masked Oral Valacyclovir	NYU Langone Health	marketed	Nucleoside analog antiviral	Viral DNA polymerase (HSV and VZV)
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
prophylactic Valganciclovir	prophylactic Valganciclovir	Rabin Medical Center	marketed	Nucleoside analog antiviral	CMV DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-09-22 — Lonsurf · RE46284 · US
• 2034-06-17 — Lonsurf · 10457666 · US
• 2034-06-17 — Lonsurf · 9527833 · US
• 2034-09-05 — Lonsurf · 9943537 · US
• 2037-02-03 — Lonsurf · 10456399 · US
• 2037-02-03 — Lonsurf · 10960004 · US

Sponsor landscape (Nucleoside analog antiviral class)

1. Merck Sharp & Dohme LLC · 3 drugs in this class
2. Hoffmann-La Roche · 2 drugs in this class
3. Göteborg University · 2 drugs in this class
4. Estetra · 1 drug in this class
5. Padagis LLC · 1 drug in this class
6. MinaPharm Pharmaceuticals · 1 drug in this class
7. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
8. NYU Langone Health · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Ain Shams University · 1 drug in this class